CGY-1, a biflavonoid isolated from cardiocrinum giganteum seeds, improves memory deficits by modulating the cholinergic system in scopolamine-treated mice
| Autor: | Ren-Wang Jiang, Rong-Rong Zhang, Xue Xia, Ze-Xin Lin, Xin-Yi Lu, Qu-Bo Chen |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
0301 basic medicine
Male Scopolamine Morris water navigation task RM1-950 Pharmacology Cholinergic Antagonists CGY-1 Cognitive disorder 03 medical and health sciences chemistry.chemical_compound Mice 0302 clinical medicine Neurotrophic factors health services administration mental disorders Animals Biflavonoids Cholinergic neurotransmission system chemistry.chemical_classification Cardiocrinum giganteum Memory Disorders biology Glutathione peroxidase Biflavonoid General Medicine Spontaneous alternation biology.organism_classification Acetylcholinesterase Choline acetyltransferase humanities Cholinergic Neurons Oxidative Stress 030104 developmental biology chemistry 030220 oncology & carcinogenesis Seeds Therapeutics. Pharmacology Lilium Drugs Chinese Herbal |
| Zdroj: | Biomedicine & Pharmacotherapy, Vol 111, Iss, Pp 496-502 (2019) |
| ISSN: | 1950-6007 |
| Popis: | Certain biflavonoids have been proven to protect against cognitive dysfunction. A new biflavonoid, CGY-1, isolated from Cardiocrinum giganteum seeds, has not yet been reported to have any neuroprotective effect. In this study, a scopolamine-induced memory deficit model was used to explore the neuroprotective effect of CGY-1. Behavioral experiments, such as tests using the Morris water maze, the Y-maze and the fear conditioning test, were conducted. The results revealed that oral administration of CGY-1 (20 and 40 mg/kg) and donepezil shortened the escape latency, improved the percentage of spontaneous alternation, and increased the freezing times, respectively. CGY-1 decreased the levels of reactive oxygen species and malondialdehyde and increased the activities of superoxide dismutase and glutathione peroxidase in the hippocampus. In addition, CGY-1 decreased the activity of acetylcholinesterase and increased the activities of choline acetyltransferase and acetylcholine in the hippocampus. Furthermore, qPCR and western blot results revealed that the expressions of neurotrophic factors, brain-derived neurotrophic factor and nerve growth factor were upregulated in the hippocampus after CGY-1 treatment. In conclusion, CGY-1 could be a promising candidate for the treatment of cognitive dysfunction. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect